skip to primary navigationskip to content

Dr Ana-Mishel Spiroski

Dr Ana-Mishel Spiroski

Research Associate

Research Interests

Adaptation to fetal deprivation and the programming of cardiometabolic disease

Although developmental plasticity and fetal adaptation to in utero adversity may be beneficial for immediate survival, fetal growth restriction (FGR) in response to deprivation occurs at the expense of cardiorespiratory development and metabolic competence. Fetal hypoxia is a common factor in complicated pregnancies with placental aetiologies and pathological processes which compromise fetal blood supply, such as that seen in uteroplacental insufficiency, and has been shown to programme postnatal cardiometabolic disease. There are currently no interventions which improve clinical outcomes in the growth-restricted offspring. Increased risk of perinatal morbidity and mortality, and a predisposition to the development of chronic disease in later life suggest that the most appropriate time to intervene in order to improve the health status of the in utero growth-restricted individual is prior to the development of postnatal complications. Dr Spiroski’s expertise integrates interdisciplinary methods, from molecular biology to systems physiology, to investigate novel fetal interventions to prevent developmental programming of chronic disease.

Key Publications

Intrauterine Intervention for the Treatment of Fetal Growth Restriction. Spiroski AM, Oliver MH, Harding JE, Bloomfield FH. Curr Pediatr Rev. 2016;12(3):168-178.

Fetal growth factors and fetal nutrition. Bloomfield FH, Spiroski AM, Harding JE. Semin Fetal Neonatal Med. 2013 Apr 30. pii: S1744-165X(13)00022-X.

Cambridge Cardiovascular logo - transparent

Logo design by Dr Ana-Mishel Spiroski and Dr Sarah Morgan.


We connect cardiovascular researchers in Cambridge.

Please follow us on Twitter for local news about research, events, funding calls, and open positions.

For inquiries about our research or the website, please contact Dr Katja Kivinen.